← The patent line

Copper Cu-64 Dotatate

Sold as DETECTNET · given by intravenous

Ten years or more until it comes off patent
15.0 yr
Until anyone may copy it
Protection runs to 2041-09-03
9
Trials running now
16 registered in total
In routine use
Furthest stage reached
already in routine clinical use
3
Organisations running trials
lead sponsors on record
01

Who owns it, and until when

Curium Us Llc
Approval holder
the only company permitted to sell it today
2041-09
Last patent expires
latest patent filed against this product
2027-09
FDA exclusivity ends
a separate protection granted at approval

Whichever date falls later is when other manufacturers may apply to sell copies. Price typically falls steeply within a year of that point, and with it any company's ability to recover the cost of new research on the molecule. That is when it becomes a candidate for the ledger on the first tab.

02

What it is being tested for

Neuroendocrine TumorsPheochromocytomaParaganglioma
03

Who is paying for the research

Rigshospitalet, Denmark
University or hospital
4
Emil Loldrup Fosbol
University or hospital
1
Grupo Espanol de Tumores Neuroendo
University or hospital
1

Who funds the trials matters after protection lapses. Company-funded work usually stops once exclusivity ends; university, hospital and government-funded work does not, and is the research most likely to continue on this molecule afterwards.

04

The trials themselves

NCT07150546Phase 12025 · 15 people · recruiting now
Combination External Radiation and PRRT for

Expiry dates are what the patent holder has filed; litigation, paediatric extensions and settlements routinely move them, so read these as the earliest plausible date rather than a schedule. Not medical advice.

← Back to the patent line